MMEM (858571)

  https://cordis.europa.eu/project/id/858571

  Horizon 2020 (2014-2020)

  Miniaturized Matrixed Enthalpy Metter - Portable, affordable, easy to operate, diagnostic device enabling a rapid & accurate diagnosis of a patient infected by antibiotic-resistant bacteria

  SME instrument (EIC-SMEInst-2018-2020)

  bacteriology  ·  DNA  ·  antibiotics  ·  sensors  ·  antibiotic resistance

  2019-07-01 Start Date (YY-MM-DD)

  2021-06-30 End Date (YY-MM-DD)

  € 3,308,056 Total Cost

  Description

Miniaturized Matrixed Enthalpy-Meter (MMEM) - a diagnostic device for a rapid and accurate diagnosis of antibiotic resistant bacteria to be used in emergency rooms, clinical laboratories, doctor offices, and other point-of-care locations. GenoSmart, is developing a novel bio-electronic molecular detection system for detection the presence of a pathogenic DNA is a biologic sample obtained from a patient. In particularly the system allows immediate detection of Carbapenem-resistant bacteria which have developed a resistance to all kinds of known antibiotics. The technology is based on a pyroelectric sensor onto a suspected DNA sample is immobilized. The system utilizes heat release during hybridization of complementary DNA molecules. If a successful hybridization between the sensor and the suspected sample molecules occurs, enthalpy (the internal energy) is released in the form of a detectable heat. The sensor immediately detects this released heat and transduces it to an electric signal. Following this detection, the result is displayed to the operator, and a decision if to isolate the patient from other patients is made. In contrast to currently available molecular detection techniques, GenoSmart MMEM device fulfills the essential need for a rapid and accurate diagnosis tool, along with a cost-effective test and without any dependency on labs and complicated facilities.The ultimate objective is to make GenoSmart's MMEM ready for market launch in Europe. This entails a number of technical and strategic objectives, including the completion of the product’s CRE detection capability, the clinical validation through a European clinical study, and the exploitation of its results (IP expansion, commercial agreements with distributors etc.). The Company plans to start sales in 2020, first in Israel as a pilot market, and gradually reaching solid penetration rate 15% of the CRE diagnosis market within 7 years.

  Complicit Organisations

1 Israeli organisation participates in MMEM.